EXCLUSIVE-NETWORKS
9.1.2020 07:02:05 CET | Business Wire | Press release
Exclusive Networks today announced the appointments of four new Senior Vice Presidents to complement its existing global leadership team. The appointments of Gerard Allison (SVP, EMEA), Brad Gray (SVP, APAC), Scott Lewis (SVP, Americas) and Barrie Desmond (SVP Marketing & Communications) will provide strategic in-theatre leadership, supporting the company’s continuing success in offering unique local and global value, whilst driving future growth through market leading technologies, innovative services, and disruptive business models, creating value at scale for both vendors and channel partners alike.
“Gerard, Brad, Scott and Barrie are highly experienced operators who will make a valuable contribution to our business in 2020 and beyond,” said Olivier Breittmayer, CEO of Exclusive Networks. “Their arrival coincides with an exciting period of business transformation and innovation as we continue to scale-up and optimise our operational processes for renewed growth in disruptive service offerings, product portfolios and business models.”
Gerard Allison is a highly experienced senior executive with a 30+ year track record of building successful teams in EMEA, working at vendors such as Juniper Networks and, most recently, Gigamon. His extensive expertise and knowledge of the IT and security markets, commercial astuteness, entrepreneurial vision, relationship building and management skills, brings a wealth of experience to the EMEA business.
Brad Gray is a highly experienced senior executive with a 25+ year track record of building successful teams in APAC at vendors such as Juniper Networks, Polycom and, most recently, SAP. Having resided for 20 years in Singapore and for 3 years previously in Indonesia, Brad’s cultural, technological and commercial insights within the region brings a wealth of knowledge and expertise to the APAC business. His appointment comes as the former ‘Asia’ and ‘Pacific’ regions of Exclusive Networks combine as a single ‘APAC’ region.
Scott Lewis is a highly experienced senior executive with a 25+ year track record of regional sales and operations leadership in the Americas, having spent nearly 20 years in the cybersecurity sector working at vendors such as Blue Coat and IBM Internet Security Systems (ISS). Scott joins Exclusive from Fortinet where he spent the last 7 years leading its US Enterprise sales organisation and most recently its US West sales teams.
Barrie Desmond returns to Exclusive following a 12 month sabbatical having previously spent 7 years as Group Marketing Director and most recently as Chief Operations Officer. Barrie has over 30 years experience in marketing, communications and business development, having held senior management roles within channel and vendor organisations, with specialist knowledge and expertise in disruptive technologies and services in cybersecurity and cloud.
The new SVPs bring a wealth of expertise and experience to Exclusive Networks having held senior regional leadership roles at leading global channel and vendor organisations. Each report to Andy Travers, Executive Vice President, Worldwide Sales and Marketing.
“Our global footprint is significant and continually expanding, which emphasises the need for strong leadership at both local and regional levels,” said Andy Travers. “Gerard, Brad, Scott and Barrie are proven business leaders with a strong track record of success and I look forward to working closely with them to take advantage of the growth opportunities within their respective regions.
Their vast experience, knowledge and skills will be a tremendous asset to our business, our partners and our people as we continue to scale-up into a new decade.”
-ends-
About Exclusive Networks
Exclusive Networks is the global specialist VAD for cybersecurity and cloud solutions – the defining and interdependent technologies of the digital era. Its capabilities are backed by best-of-breed vendor portfolios, unparalleled skills and a host of compelling services from pre and post-sales technical support to leasing, training, professional services and global project management. With 50+ offices across five continents and presence in over 100 countries, Exclusive Networks has a unique ‘local sale, global scale’ model, enabling partners to achieve global reach, while delivering the added value of a locally-focused specialist distributor. More at www.exclusive-networks.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005671/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom